Download - Case-Control Studies: An Example
![Page 1: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/1.jpg)
CASE-CONTROL STUDIES:AN EXAMPLEEP 711
November 8, 2011
1
![Page 2: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/2.jpg)
Issues in Study Design and Interpretation• Type of study• Case definition• Control definition• Sources of exposure information• Exposure definition• Potential confounders• Potential sources of bias
2
![Page 3: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/3.jpg)
Louik C et al: N Engl J Med 2007;356:2675-83
3
![Page 4: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/4.jpg)
Background• ≥10% of pregnant women experience depressive
symptoms in pregnancy• Medications represent one treatment option• SSRIs first marketed in 1988 and gained widespread
acceptance• RDD survey in 2005 indicated that among women aged 18-44,
~8% used an SSRI in the week preceding interview
4
![Page 5: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/5.jpg)
Background• Advantages of SSRIs
• Established efficacy• Favorable side effect profile• Serum monitoring not required• Toxicity/overdose not a major problem
5
![Page 6: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/6.jpg)
Background• SSRIs include
• Fluoxetine (Prozac)• Sertraline (Zoloft)• Paroxetine (Paxil)• Citalopram (Celexa)• Fluvoxamine (Luvox)• Escitalopram (Lexapro)
6
![Page 7: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/7.jpg)
Background• Congenital malformations
• Major defects affect about 2-3% of livebirths• Encompasses a wide variety of defects• Some are extremely rare, e.g. limb reduction defects (2-4/10,000)• Others are more common, e.g. cleft lip (1/700), neural tube defects
(1/1000)• Heart defects occur about 1/200 births
7
![Page 8: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/8.jpg)
Background• Initial studies
• Small cohorts from pregnancy registries• Results reassuring with respect to birth defects overall
8
![Page 9: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/9.jpg)
Background• Later studies
• Larger• Found no increased risk for birth defects overall, but
• Increased risk for some specific defects• 3 independent studies reported increased risk for heart defects
9
![Page 10: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/10.jpg)
Objectives• Examine 1st trimester use of specific SSRIs in relation to
specific birth defects• Test existing hypotheses
• Craniosynostosis• Omphalocele• Heart defects
• Explore other defects not yet reported
• Focus on specificity to help reduce misclassification
10
![Page 11: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/11.jpg)
![Page 12: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/12.jpg)
Choice of Study Design• Birth defects occur in 2-3% of livebirths (not uncommon)• Short latent period (9 months)• So why not cohort??
12
![Page 13: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/13.jpg)
Choice of Study Design• “Birth Defects” is NOT a single outcome, and individually,
THEY ARE RARE• Major birth defects affect 2-3% of newborns• However, specific defects typically affect only ~2/1000 to 1/10,000
• Known teratogens typically increase the risk of a specific defect or a group of related defects (syndrome or sequence)
13
![Page 14: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/14.jpg)
Choice of Study Design• Therefore, a case-control approach is better suited to our
research question looking at specific defects.
14
![Page 15: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/15.jpg)
Types of Case-Control Studies
Specific Semi-Specific Non-Specific
![Page 16: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/16.jpg)
Methods
• Study subjects• Infants with any of a wide range of malformations (isolated
minor defects excluded)• Sample of non-malformed infants from same birth hospitals
16
![Page 17: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/17.jpg)
Methods
• Identified in 5 study centers• Study staff review clinic/surgical logs,
admission/discharge lists, contact newborn nursery and labor/delivery rooms
• In 2 study centers, use statewide birth defects registries
• Nonmalformed infants identified at study hospitals• In Mass., population-based random sample of
newborns
17
![Page 18: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/18.jpg)
Methods
• Mothers interviewed within 6 months of birth• Trained study nurses• By telephone• Questions address
• Demographics• Reproductive history• Medical history• Lifestyle habits• Detailed medication history (includes prescription, over-the-counter,
and herbal products)
18
![Page 19: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/19.jpg)
Case definition--Theory• Specific as possible• Strict criteria• Should be reasonable to think that they have a common
etiology
19
![Page 20: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/20.jpg)
Case Definition--Applied• Cases are infants with heart defects
• Concerns• No rigorous definition• Not homogeneous
• Solution• Blind review of all infants with a heart-related defect• Sub-classify into embryologically meaningful groups to increase
homogeneity
20
![Page 21: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/21.jpg)
Case Definition--Applied
• Case subgroups• Looping, laterality, and single ventricle defects• Conotruncal defects• Atrioventricular canal defects• Right ventricular outflow tract obstruction defects• Left ventricular outflow tract obstruction defects• Septal defects• Anomalous pulmonary venous return
21
![Page 22: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/22.jpg)
Normal Heart
![Page 23: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/23.jpg)
Pulmonary Valve Stenosis
23
![Page 24: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/24.jpg)
Ventricular Septal Defect
24
![Page 25: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/25.jpg)
Control Definition--Theory• Sample of the population that produced the cases• Sampled independently of exposure status
25
![Page 26: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/26.jpg)
Control Definition--Applied• Infants with other malformations
• Advantages• From same population as cases• Should remember pregnancy events similarly to cases
• Disadvantages• May not reflect exposure status in population that gave rise to cases, i.e.
exposure may be associated with increased risk of these defects too
26
![Page 27: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/27.jpg)
Control Definition--Applied• Nonmalformed infants
• Advantages• From same population as cases• Should reflect exposure status in the population that gave rise to cases
• Disadvantages• May remember pregnancy events differently than cases (recall bias)
27
![Page 28: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/28.jpg)
Control Definition--Applied• We will use nonmalformed controls
• Address disadvantages by• Asking focused exposure questions (evidence exists that this enhances
recall)• Considering other antidepressants (recall bias, if present, should apply
to these too)
28
![Page 29: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/29.jpg)
Exposure Assessment--Theory• Need sufficient detail of nature, duration, and timing of
exposure• Accuracy is critically important• Sources of Information
• Biomarkers• Records• Interviews
29
![Page 30: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/30.jpg)
Exposure Assessment--Applied• Biomarkers—not applicable• Records
• Medical records• Multiple providers• Prescription ≠ Consumption• Complete?
• Pharmacy• No OTC meds, herbals• Dispense ≠ Use
30
![Page 31: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/31.jpg)
Exposure Assessment--Applied• Interview
• Greater detail available• Potentially includes all drugs• Relies on mother’s recollection
• Because we chose to use nonmalformed controls, may differ between cases and controls (recall bias)
31
![Page 32: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/32.jpg)
Source of Selected Prescription Drugs 5,435
Mothers; Boston, Philadelphia, Toronto, Iowa, 1976-1984
Total
Source (in %)
Drug
Users Physician’s Prescription
Other
Bendectin
859
98
1
Valium 135 82 18 Fiorinal 105 96 4 Hydrodiuril 76 97 3 Clomid 66 100 0 Compazine 59 91 9 Darvon 42 78 22 Seconal 42 95 5 Diuril 27 85 11
32
Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670‑6.
![Page 33: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/33.jpg)
33
Exposure Assessment
J Womens Health (Larchmt). 2008 Sep;17(7):1073-80.
Prescription medication borrowing and sharing among women of reproductive age.
Petersen EE, Rasmussen SA, Daniel KL, Yazdy MM, Honein MA.
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
33
![Page 34: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/34.jpg)
34
Exposure Assessment
• Overall, 28.8% of women and 26.5% of men reported ever borrowing or sharing prescription medications.
• Women of reproductive age were more likely to report prescription medication borrowing or sharing (36.5%) than women of nonreproductive age (>or=45 years) (19.5%)
34
![Page 35: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/35.jpg)
35
35
A quarter of new prescriptions go unfilled, study findsFebruary 18, 2010
![Page 36: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/36.jpg)
36
Exposure Assessment
More than a quarter of new prescriptions are unfilled, especially when the drugs are for symptomless conditions, researchers from Boston's Brigham and Women's Hospital have found. Physicians have long been concerned that many patients fill new prescriptions one time, then never get refills. But it has been impossible in the past to determine adherence to new prescriptions. The new study was made possible by the implementation of an electronic-prescribing initiative by two Massachusetts health plans.
36
![Page 37: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/37.jpg)
Exposure Assessment—Evidence of Completeness*
• False negatives• Valium reports—1975
• Medical records—1.2%• Maternal interview—5.8%
• 20% from sources other than physician
• Bendectin—late 1970’s, used exclusively in pregnancy• Manufacturer’s data—25%• Interview data—24%
37
*Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670‑6.
![Page 38: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/38.jpg)
Exposure Assessment—Evidence of Completeness*
• False positives• Elamar
38
*Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670‑6.
![Page 39: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/39.jpg)
Exposure Assessment—Addressing Recall Bias
• If recall is complete, recall bias cannot exist• Enhancement of recall will diminish recall bias
39
![Page 40: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/40.jpg)
Reported Drug Use by Question Asked532 Women; Boston - 1975, and Toronto - 1978
Drug
Percent Ascertained by
Total Users
Open-ended Indication Name (n)
Prescription Drugs
Valium 21 55 26 (90)
Fiorinal 37 35 28 (43)
Darvon 23 45 32 (40)
Non-Prescription Drugs
Aspirin 1 79 20 (377)
Acetaminophen 2 55 43 (177)
Am J Epidemiol 1986; 123:670-6.
40
![Page 41: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/41.jpg)
Exposure Assessment
•Series of questions about medications used any time from 2 months prior to LMP through the pregnancy• Illnesses they may have had, and medications used
41
![Page 42: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/42.jpg)
Exposure Assessment• List of indications for which medications might be used
• Anxiety, depression, other psychological conditions
• Use of specific medications• Prozac, Zoloft, Paxil, Effexor, Elavil, Celexa, Luvox, Lexapro,
Wellbutrin
42
![Page 43: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/43.jpg)
Exposure Assessment—Details• Timing
• First trimester• 28 days prior to LMP through the 4th lunar month
• Nature• Any SSRI• Specific SSRI• Non-SSRI antidepressants
• Helps assess presence of recall bias• Helps assess “confounding by indication”
43
![Page 44: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/44.jpg)
Exposure Assessment• Referent group
• Women who reported no exposure to any antidepressant at any time (56 days prior to LMP through the pregnancy)
• Exclusions• Women whose only exposure was either 28-56 days prior to LMP
or after the 4th lunar month
44
![Page 45: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/45.jpg)
Potential confounders• Factors related to exposure and to outcome that explain
results• Maternal age Parity• Maternal race/ethnicity History of seizures,
diabetes, hypertension• Maternal education Infertility• Smoking history Folic acid use• Alcohol consumption LMP year• Family history of birth defects Study center• BMI
45
![Page 46: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/46.jpg)
Results
• 5,860 nonmalformed infants• Rate of exposure to any SSRI in controls—2.8%
46
![Page 47: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/47.jpg)
Results• 3,724 infants with congenital heart defects (100
exposed)• 186 looping, laterality defects (2 exposed)• 620 conotruncal defects (13 exposed)• 164 atrioventricular defects (0 exposed)• 363 RVOTO (15 exposed)• 482 LVOTO defects (15 exposed)• 1161 septal defects (32 exposed)• 17 anomalous pulmonary venous return (0 exposed)
47
![Page 48: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/48.jpg)
All cardiac defects
Cases Controls OR
(95% CI)
Any SSRI 2.7% 2.7% 1.2
(0.9, 1.6)
Non SSRI
Antidepressant
0.6% 0.8% 0.8
(0.5, 1.5)
48
![Page 49: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/49.jpg)
Results• Create more homogeneous classes
• Specific cardiac defects• Septal defects• RVOTO defects
• Specific SSRIs• Fluoxetine• Sertraline• Paroxetine
49
![Page 50: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/50.jpg)
Septal defects
Cases Controls OR
95% CI
Fluoxetine 0.9% 1.1% 1.0
(0.5, 2.2)
Sertraline 1.1% 0.8% 2.0
(1.2, 4.0)
Paroxetine 0.5% 0.5% 0.8
(0.3, 2.2)
Non-SSRI
Anti-depressants
0.9% 0.9% 1.1
(0.6, 2.4)
50
![Page 51: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/51.jpg)
RVOTO Defects
Cases Controls OR
(95% CI)
Fluoxetine 1.1% 1.0% 1.0
(0.2, 3.4)
Sertraline 0.8% 0.8% 2.0
(0.6, 6.8)
Paroxetine 1.7% 0.5% 3.3
(1.3, 8.8)
Non-SSRIAnti-depressants
0.6% 0.8% 0.9
(0.2, 3.8)
51
![Page 52: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/52.jpg)
Interpretation
• Possible explanations for findings• Selection bias• Information bias• Confounding• Chance• “Real”
52
![Page 53: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/53.jpg)
Interpretation
• Selection bias• Not population-based, so must be considered• Is entry into study related to exposure
• “medicalization”? • These are serious defects, unlikely to escape detection
• Differential effects among SSRIs and no effect for non-SSRI antidepressants
53
![Page 54: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/54.jpg)
Interpretation
• Information bias• Interviewers “blind” to hypothesis• Recall bias
• Structured interview• Antidepressants used on a regular basis• Antidepressants used for non-trivial indications
• Null effect for non-SSRI antidepressants
54
![Page 55: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/55.jpg)
Interpretation
• Confounding• Many demographic, medical, reproductive, and
administrative variables “controlled” for in analysis• “confounding by indication”
• No increased risk for non-SSRI antidepressants
• Uncontrolled confounding by factors not considered is always possible
55
![Page 56: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/56.jpg)
Interpretation
• Chance• Can never be ruled out• In this study, many comparisons were made, so
possibility of chance findings are increased• Place greatest reliance on those findings that are
consistent with other studies
56
![Page 57: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/57.jpg)
RVOTO Defects (NBDPS data)
Fluoxetine Sertraline Paroxetine
No. of infants
No. Adjusted OR
(95%CI)
No. Adjusted OR
(95%CI)
No. Adjusted OR
(95%CI)
RVOTO 669 4 0.9
(0.4-2.1)
4 0.8
(0.3-2.3)
7 2.5
(1.0-6.0)
Controls 4092 29 32 18
57
Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk ofbirth defects. N Engl J Med 2007; 356:2684-92
![Page 58: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/58.jpg)
Conclusions• This study does not support overall effect with cardiac
defects, but does find evidence of associations for specific SSRIs with specific cardiac defects• Paroxetine and RVOTO • Sertraline and septal
58
![Page 59: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/59.jpg)
Conclusions• Specific SSRIs may increase the risk of specific birth
defects• Absolute risks still small
• Baseline prevalence of RVOTO: about 5.5 cases per 10,000 livebirths
• 4-fold increase in risk means that the absolute risk is only 0.2%.
59
![Page 60: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/60.jpg)
Conclusions
• Depression in pregnancy is not a good thing for the mother or her infant.
• As with any therapeutic decision, one must weigh the risk of possible adverse outcomes with the benefits of treating depressed women with any SSRI and with specific SSRIs.
60
![Page 61: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/61.jpg)
![Page 62: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/62.jpg)
62
![Page 63: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/63.jpg)
Source of Selected Prescription Drugs 5,435
Mothers; Boston, Philadelphia, Toronto, Iowa, 1976-1984
Total
Source (in %)
Drug
Users Physician’s Prescription
Other
Bendectin
859
98
1
Valium 135 82 18 Fiorinal 105 96 4 Hydrodiuril 76 97 3 Clomid 66 100 0 Compazine 59 91 9 Darvon 42 78 22 Seconal 42 95 5 Diuril 27 85 11
63
Am J Epidemiol 1986; 123:670-6.
![Page 64: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/64.jpg)
Fetal Circulation
64
![Page 65: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/65.jpg)
Circulation after birth
65
![Page 66: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/66.jpg)
![Page 67: Case-Control Studies: An Example](https://reader035.vdocument.in/reader035/viewer/2022062321/56812acf550346895d8eace6/html5/thumbnails/67.jpg)
67